When do you start to see weight loss on Wegovy?

What STEP 1 shows about the early weeks

The STEP 1 trial is the clearest evidence base for understanding when weight loss on Wegovy tends to appear. Participants began at 0.25mg weekly and titrated upward every four weeks, reaching the 2.4mg maintenance dose at around week 16. Across the cohort, measurable weight reduction was already detectable by week four — but the rate of loss was modest at this point. The first pen is largely about helping the body adjust: slower gastric emptying and reduced appetite kick in quickly, but the body's energy deficit needs time to translate into kilogram-level changes on the scales.

A practical habit worth building early: weigh yourself on the same day each week, at the same time of day, wearing roughly the same clothes. Day-to-day fluctuations of 0.5–1.5kg are normal and are mostly water and digestive contents. A weekly average smooths this out and gives you a far more honest read on progress.

By week eight, most participants in STEP 1 had lost between 3% and 5% of their starting weight. If you want a detailed breakdown of what to expect at each stage, our page on how long before you see weight loss on Wegovy walks through the timeline week by week. That might feel slow if you are expecting rapid early results, but it reflects how the medicine is designed to work: a steady, sustained reduction rather than a sharp drop.

Why the middle of treatment is often where the real momentum builds

One pattern that surprises people is that the fastest monthly losses in STEP 1 did not happen at the start. As the dose climbs through 1.0mg and 1.7mg toward 2.4mg, the appetite-suppressing effect strengthens. Participants who had lost 4–6% by week 12 often found that weeks 16 through 36 delivered their largest incremental reductions. This is the phase when the prescriber has confirmed the maintenance dose and the body is responding to it fully.

This matters for managing expectations. If you are still at 0.25mg or 0.5mg and progress feels limited, that is not a sign the medicine is not working for you, it reflects where you are on the dose schedule. The timeline for Wegovy to reach its full effect is closely tied to the titration pathway, which a prescriber controls based on tolerability, not speed.

It is also worth understanding that the 15% average figure in STEP 1 is an average across a large and varied group. Individual results ranged considerably: some participants lost more, others less. Biology, starting weight, diet changes made alongside treatment, and activity levels all contribute. The trial included lifestyle support alongside the injection, context the NICE appraisal of semaglutide (TA875) also emphasises, recommending Wegovy within a structured weight management programme.

What to expect if results feel slower than you hoped

A question our prescribers hear regularly is whether slower-than-expected progress means something is wrong. In most cases, the answer is no. Several factors can mask real fat loss in the early weeks: increased water retention if activity has gone up, normal hormonal fluctuations, constipation (itself a common early side effect of GLP-1 medicines), and the simple fact that 0.25mg is a tolerability dose rather than a full therapeutic one.

The relevant clinical benchmark is a 5% reduction from starting weight after six months on the maintenance dose. If that threshold has not been reached, continuing treatment would be reviewed. That is a prescriber-level conversation, not a self-assessment, and it is one of the reasons clinical re-review before every repeat order matters. If you are thinking about when results on Wegovy are typically noticeable in a longer-term context, the evidence consistently points to the six-month mark as a meaningful checkpoint.

Side effects, particularly nausea and reduced appetite in the first few weeks, can also affect eating patterns in ways that influence the timeline. These typically settle as the body adapts, but they do affect how much someone eats in those early weeks, which can mean slightly faster initial changes in some people. For a fuller picture of what to expect on Wegovy, the Wegovy overview covers both the mechanism and the broader evidence base.

How the 7.2mg dose changes the picture

In January 2026 the MHRA approved a higher 7.2mg maintenance dose of semaglutide (Wegovy), and in April 2026 approved a dedicated single-dose 7.2mg pen. Trial data at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results and representing a meaningful step up from the 2.4mg figure. The titration pathway still starts at 0.25mg, so the timeline question remains the same for the early months: steady accumulation across the dose schedule, with the largest reductions appearing once the maintenance level is reached and sustained.

If you want to understand how long weight loss on Wegovy typically takes at each stage, the short answer is that it is a months-long process by design. The 68- and 72-week trial periods were not arbitrary, they reflect how long it takes for clinically significant, sustained fat loss to occur. Whether the 7.2mg dose is appropriate for a given individual is a clinical decision made at consultation, not something determined by the dose schedule alone.

If you are weighing up your options or want to understand the cost of private treatment alongside the clinical picture, the Wegovy cost page sets out what a private prescription typically involves. And if you are ready to find out whether you are eligible, check your eligibility with our prescribers, the consultation is free and reviewed the same day by a GPhC-registered Independent Prescriber.